Atopic dermatitis: a review of evolving targeted therapies

References

• Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387:1109–1122.
   PubMed Web of Science ®Google Scholar
• Bieber T, D’Erme AM, Akdis CA, et al. Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should we go? J Allergy Clin Immunol. 2017;139(4S):S58–S64.
   PubMed Web of Science ®Google Scholar
• Dharmage SC, Lowe AJ, Matheson MC, et al. Atopic dermatitis and the atopic march revisited. Allergy. 2014;69(1):17–27.
   PubMed Web of Science ®Google Scholar
• Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(Suppl 1):8–16.
   PubMed Web of Science ®Google Scholar
• Mu Z, Zhao Y, Liu X, et al. Molecular biology of atopic dermatitis. Clin Rev Allergy Immunol. 2014;47(2):193–218.
   PubMed Web of Science ®Google Scholar
• Nograles KE, Zaba LC, Shemer A, et al. IL-22-producing “T22ʹ’ T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol. 2009;123(6):1244–1252.
   PubMed Web of Science ®Google Scholar
• D’Erme AM, Romanelli M, Chiricozzi A. Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy. Drug Des Devel Ther. 2017;11:1473–1480.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007;445(7128):648–651.
   PubMed Web of Science ®Google Scholar
• Kaminishi K, Soma Y, Kawa Y, et al. Flow cytometric analysis of IL-4, IL-13 and IFN-gamma expression in peripheral blood mononuclear cells and detection of circulating IL-13 in patients with atopic dermatitis provide evidence for the involvement of type 2 cytokines in the disease. J Dermatol Sci. 2002;29(1):19–25.
   PubMed Web of Science ®Google Scholar
• Akkoc T, de Koning PJ, RüCkert B, et al. Increased activation-induced cell death of high IFN-gamma producing T(H)1 cells as a mechanism of T(H)2 predominance in atopic diseases. J Allergy Clin Immunol. 2008;121(3):652–658.e1.
   PubMed Web of Science ®Google Scholar
• Megna M, Napolitano M, Patruno C, et al. Systemic treatment of adult atopic dermatitis: a review. Dermatol Ther (Heidelb). 2017;7(1):1–23.
   PubMed Web of Science ®Google Scholar
• Garritsen FM, Roekevisch E, van der Schaft J, et al. Ten years experience with oral immunosuppressive treatment in adult patients with atopic dermatitis in two academic centres. J Eur Acad Dermatol Venereol. 2015;29(10):1905–1912.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013;132(5):1132–1138.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Megna M, Patruno C, et al. Adult atopic dermatitis: a review. G Ital Dermatol Venereol. 2016;151(4):403–411.
   PubMed Web of Science ®Google Scholar
• Vakharia PP, Silverberg JI. New therapies for atopic dermatitis: additional treatment classes. J Am Acad Dermatol. 2018;78(3S1):S76–S83.
   PubMed Web of Science ®Google Scholar
• Howell MD, Parker ML, Mustelin T, et al. Past, present, and future for biologic intervention in atopic dermatitis. Allergy. 2015;70(8):887–896.
   PubMed Web of Science ®Google Scholar
• DaVeiga SP. Epidemiology of atopic dermatitis: a review. Allergy Asthma Proc. 2012;33(3):227–234.
   PubMed Web of Science ®Google Scholar
• Spergel JM. From atopic dermatitis to asthma: the atopic march. Ann Allergy Asthma Immunol. 2010;105(2):99–106.
   PubMed Web of Science ®Google Scholar
• Bieber T. Atopic dermatitis. N Engl J Med. 2008;358:1483–1494.
   PubMed Web of Science ®Google Scholar
• Suarez-Farinas M, Dhingra N, Gittler J, et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol. 2013;132(2):361–370.
   PubMed Web of Science ®Google Scholar
• Martel BC, Litman T, Hald A, et al. Distinct molecular signatures of mild extrinsic and intrinsic atopic dermatitis. Exp Dermatol. 2016;25(6):453–459.
   PubMed Web of Science ®Google Scholar
• Gooderham M, Lynde CW, Papp K, et al. Review of systemic treatment options for adult atopic dermatitis. J Cutan Med Surg. 2017;21(1):31–39.
   PubMed Web of Science ®Google Scholar
• Harskamp CT, Armstrong AW. Immunology of atopic dermatitis: novel insights into mechanisms and immunomodulatory therapies. Semin Cutan Med Surg. 2013;32(3):132–139.
   PubMed Web of Science ®Google Scholar
• Mansouri Y, Guttman-Yassky E. Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics. J Clin Med. 2015;4(5):858–873.
   PubMed Web of Science ®Google Scholar
• Lauffer F, Ring J. Target-oriented therapy: emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs. 2016;21(1):81–89.
   PubMed Web of Science ®Google Scholar
• Suárez-Fariñas M, Tintle SJ, Shemer A, et al. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol. 2011;127(4):954–64.e1–e4.
   PubMed Web of Science ®Google Scholar
• Hamilton JD, Suárez-Fariñas M, Dhingra N, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014;134(6):1293–1300.
   PubMed Web of Science ®Google Scholar
• Beck LA, Thaci D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–139.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Bieber T. Proactive therapy of atopic dermatitis – an emerging concept. Allergy. 2009;64(2):276–278.
   PubMed Web of Science ®Google Scholar
• Thaci D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo- controlled, dose-ranging phase 2b trial. Lancet. 2016;387(10013):40–52.
   PubMed Web of Science ®Google Scholar
• Brunner PM, Guttman-Yassky E, Leung DYM. The immunology of atopic dermatitis and its reversibility with broad spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139(4S):S65–S76.
   PubMed Web of Science ®Google Scholar
• Hamilton JD, Ungar B, Guttman-Yassky E. Drug evaluation review: dupilumab in atopic dermatitis. Immunotherapy. 2015;7(10):1043–1058.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348.
   PubMed Web of Science ®Google Scholar
• Blakely K, Gooderham M, Papp K. Dupilumab, a monoclonal antibody for atopic dermatitis: a review of current literature. Skin Therapy Lett. 2016;21(2):1–5.
   PubMedGoogle Scholar
• D’Erme AM. The beginning of biological treatment era in the atopic dermatitis management. Dermatol Ther. 2016;29(3):208–209.
   PubMed Web of Science ®Google Scholar
• Antoniu SA. Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema. Curr Opin Invest Drugs. 2010;11(11):1286–1294.
   PubMedGoogle Scholar
• McGregor S, Farhangian ME, Feldman SR. Dupilumab for the treatment of atopic dermatitis: a clinical trial review. Expert Opin Biol Ther. 2015;15(11):1657–1660.
   PubMed Web of Science ®Google Scholar
• Hambly N, Nair P. Monoclonal antibodies for the treatment of refractory asthma. Curr Opin Pulm Med. 2014;20(1):87–94.
   PubMed Web of Science ®Google Scholar
• Montes-Torres A, Llamas-Velasco M, Pérez-Plaza A, et al. Biological treatments in atopic dermatitis. J Clin Med. 2015;4(4):593–613. a.
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov [Internet]. A phase 2a study to investigate the effects of repeated administration of Aeroderm in subjects with atopic eczema. Bethesda (MD): ClinicalTrials.gov; 2008 May 13 [cited 2017 Dec 17]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00676884
   Google Scholar
• Hamann CR, Thyssen JP. Monoclonal antibodies against IL-13 and IL-31RA in development for atopic dermatitis. J Am Acad Dermatol. 2018;78(3):S37–S42. a.
   PubMed Web of Science ®Google Scholar
• Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2009;124(3 Suppl 2):R7–R12.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Howell MD, Guttman-Yassky E, et al. A phase 2b dose-ranging efficacy and safety study of tralokinumab in adult patients with moderate to severe atopic dermatitis (AD). J Am Acad Dermatol. 2017;76(6, Supplement 1):AB20.
   Web of Science ®Google Scholar
• Renert-Yuval Y, Guttman-Yassky E. The changing landscape of alopecia areata: the therapeutic paradigm. Adv Ther. 2017;34(7):1594–1609.
   PubMed Web of Science ®Google Scholar
• Popovic B, Breed J, Rees DG, et al. Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Rα1 and IL-13Rα2. J Mol Biol. 2017;429(2):208–219.
   PubMed Web of Science ®Google Scholar
• Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425–437.
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov [Internet]. Tralokinumab monotherapy for moderate to severe atopic dermatitis - ECZTRA 1 (ECZema tralokinumab trial no. 1) (ECZTRA 1). Bethesda (MD): ClinicalTrials.gov; 2017 Apr 27 [cited 2017 Jul 17]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT03131648?view=results
   Google Scholar
• Piper E, Brightling C, Niven R, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J. 2013;41(2):330–338.
   PubMed Web of Science ®Google Scholar
• Ultsch M, Bevers J, Nakamura G, et al. Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab. J Mol Biol. 2013;425(8):1330–1339.
   PubMed Web of Science ®Google Scholar
• Simpson E, Flohr C, Eichenfield L. Efficacy and safety of lebrikizumab in patients with atopic dermatitis: a Phase II randomized, controlled trial (TREBLE). J Am Acad Dermatol. 2018;78(5):863–871.
   PubMed Web of Science ®Google Scholar
• Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365(12):1088–1098.
   PubMed Web of Science ®Google Scholar
• Oldhoff JM, Darsow U, Werfel T, et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy. 2005;60(5):693–696.
   PubMed Web of Science ®Google Scholar
• Molfino NA, Gossage D, Kolbeck R, et al. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin Exp Allergy. 2012;42(5):712–737.
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Ying S, Phipps S, et al. Interactions between eotaxin, histamine and mast cells in early microvascular events associated with eosinophil recruitment to the site of allergic skin reactions in humans. Clin Exp Allergy. 2004;34(8):1276–1282.
   PubMed Web of Science ®Google Scholar
• Wang HH, Li YC, Huang YC. Efficacy of omalizumab in patients with atopic dermatitis: a systematic review and meta-analysis. J Allergy Clin Immunol. 2016;138(6):1719–1722.e1.
   PubMed Web of Science ®Google Scholar
• Simon D, Braathen LR, Simon HU. Eosinophils and atopic dermatitis. Allergy. 2004;59(6):561–570.
   PubMed Web of Science ®Google Scholar
• Phipps S, Flood-Page P, Menzies-Gow A, et al. Intravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergen-challenged human atopic skin. J Invest Dermatol. 2004;122(6):1406–1412.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Efficacy and safety study of mepolizumab in subjects with moderate to severe atopic dermatitis. Bethesda (MD): ClinicalTrials.gov; 2017. [cited 2018 Jun 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT03055195?term=NCT03055195&rank=1
   Google Scholar
• Grimstad O, Sawanobori Y, Vestergaard C, et al. Anti-interleukin-31 antibodies ameliorate scratching behaviour in NC/Nga mice: A model of atopic dermatitis. Exp Dermatol. 2009;18(1):35–43.
   PubMed Web of Science ®Google Scholar
• Gittler JK, Shemer A, Suarez-Farinas M, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130(6):1344–1354.
   PubMed Web of Science ®Google Scholar
• Nobbe S, Dziunycz P, MüHleisen B, et al. IL-31 expression by inflammatory cells is preferentially elevated in atopic dermatitis. Acta Derm Venereol. 2012;92(1):24–28.
   PubMed Web of Science ®Google Scholar
• Rabenhorst A, Hartmann K. Interleukin-31: a novel diagnostic marker of allergic diseases. Curr Allergy Asthma Rep. 2014;14(4):423.
   PubMed Web of Science ®Google Scholar
• ClnicalTrials.gov [Internet]. A two-part, Phase 1, randomized, double-blind, placebo-controlled, single-dose, dose- escalation study of subcutaneous and intravenous administration of IL-31 mAb (Anti- Interleukin 31 monoclonal antibody; BMS-981164) in healthy subjects and adult subjects with atopic dermatitis. Bethesda (MD): ClinicalTrials.gov; 2012 [cited 2017 Jan 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT01614756
   Google Scholar
• Ruzicka T, Hanifin JM, Furue M, et al. Anti-interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med. 2017;376(9):826–835.
   PubMed Web of Science ®Google Scholar
• Nemoto O, Furue M, Nakagawa H, et al. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2016;174(2):296–304.
   PubMed Web of Science ®Google Scholar
• Saleem M, Oussedik E, D’Amber V, et al. Interleukin-31 pathway and its role in atopic dermatitis: a systematic review. J Dermatol Treat. 2017;28(7):591–599.
   PubMed Web of Science ®Google Scholar
• Nakajima S, Igyarto BZ, Honda T, et al. Langerhans cells are critical in epicutaneous sensitization with protein antigen via thymic stromal lymphopoietin receptor signaling. J Allergy Clin Immunol. 2012;129(4):1048–1055.
   PubMed Web of Science ®Google Scholar
• Kubo T, Kamekura R, Kumagai A, et al. ∆Np63 controls a TLR3-mediated mechanism that abundantly provides thymic stromal lymphopoietin in atopic dermatitis. PLoS ONE. 2014;9(8):e105498.
   PubMed Web of Science ®Google Scholar
• Ziegler SF, Liu YJ. Thymic stromal lymphopoietin in normal and pathogenic T cell development and function. Nat Immunol. 2006;7(7):709–714.
   PubMed Web of Science ®Google Scholar
• Wang YH, Liu YJ. Thymic stromal lymphopoietin, OX40-ligand, and interleukin-25 in allergic responses. Clin Exp Allergy. 2009;39(6):798–806.
   PubMed Web of Science ®Google Scholar
• Liu YJ. Thymic stromal lymphopoietin and OX40 ligand pathway in the initiation of dendritic cell-mediated allergic inflammation. J Allergy Clin Immunol. 2007;120(2):238–244.
   PubMed Web of Science ®Google Scholar
• Tidwell WJ, Fowler JF Jr. T-cell inhibitors for atopic dermatitis. J Am Acad Dermatol. 2018;78(3S1):S67–S70.
   PubMedGoogle Scholar
• Gauvreau GM, O’Byrne PM, Boulet LP, et al. Effects on an anti-TSLP antibody on allergen- induced asthmatic response. N Engl J Med. 2014;370(22):2102–2110.
   PubMed Web of Science ®Google Scholar
• AstraZeneca [Internet]. Year-to-date and Q3 2017 results. Cambridge: AstraZenea; 2017 Nov 9 [cited 2018 Aug 10]. Available from: https://www.astrazeneca.com/content/dam/az/PDF/2017/Q3/Year-to-date_and_Q3_2017_Results_Announcement.pdf
   Google Scholar
• Holm JG, Agner T, Sand C, et al. Omalizumab for atopic dermatitis: case series and a systematic review of the literature. Int J Dermatol. 2017;56(1):18–26.
   PubMed Web of Science ®Google Scholar
• Godse K, Mehta A, Patil S, et al. Omalizumab—a review. Indian J Dermatol. 2015;60(4):381–384.
   PubMed Web of Science ®Google Scholar
• Heil PM, Maurer D, Klein B, et al. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course—a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges. 2010;8(12):990–998.
   PubMed Web of Science ®Google Scholar
• Thaiwat S, Sangasapaviliya A. Omalizumab treatment in severe adult atopic dermatitis. Asian Pac J Allergy Immunol. 2011;29(4):357–360.
   PubMed Web of Science ®Google Scholar
• Park SY, Choi MR, Na JI, et al. Recalcitrant atopic dermatitis treated with omalizumab. Ann Dermatol. 2010;22(3):349–352.
   PubMed Web of Science ®Google Scholar
• El-Qutob D. Off-label uses of omalizumab. Clin Rev Allergy Immunol. 2016;50(1):84–96.
   PubMed Web of Science ®Google Scholar
• Amrol D. Anti-immunoglobulin e in the treatment of refractory atopic dermatitis. South Med J. 2010;103(6):554–558.
   PubMed Web of Science ®Google Scholar
• Fernandez-Anton Martinez MC, Leis-Dosil V, Alfageme-Roldan F, et al. Omalizumab for the treatment of atopic dermatitis. Actas Dermosifiliogr. 2012;103(7):624–628.
   PubMedGoogle Scholar
• Forman SB, Garrett AB. Success of omalizumab as monotherapy in adult atopic dermatitis: case report and discussion of the high-affinity immunoglobulin E receptor, FcepsilonRI. Cutis. 2007;80(1):38–40.
   PubMed Web of Science ®Google Scholar
• Belloni B, Ziai M, Lim A, et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol. 2007;120(5):1223–1225.
   PubMed Web of Science ®Google Scholar
• Quist SR, Ambach A, Go ̈Ppner D, et al. Long-term treatment of severe recalcitrant atopic dermatitis with omalizumab, an anti-immunoglobulin E. Acta Derm Venereol. 2013;93(2):206–208.
   PubMed Web of Science ®Google Scholar
• Vigo PG, Girgis KR, Pfuetze BL, et al. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol. 2006;55(1):168–170.
   PubMed Web of Science ®Google Scholar
• Incorvaia C, Pravettoni C, Mauro M, et al. Effectiveness of omalizumab in a patient with severe asthma and atopic dermatitis. Monaldi Arch Chest Dis. 2008;69(2):78–80.
   PubMedGoogle Scholar
• Lee E, Sheinkopf LE, Asif W, et al. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol. 2006;55(1):168–170.
   PubMed Web of Science ®Google Scholar
• Kim DH, Park KY, Kim BJ, et al. Anti-immunoglobulin E in the treatment of refractory atopic dermatitis. Clin Exp Dermatol. 2013;38(5):496–500.
   PubMed Web of Science ®Google Scholar
• Sheinkopf LE, Rafi AW, Do LT, et al. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc. 2008;29(5):530–537.
   PubMed Web of Science ®Google Scholar
• Zink A, Gensbaur A, Zirbs M, et al. Targeting IgE in severe atopic dermatitis with a combination of immunoadsorption and omalizumab. Acta Derm Venereol. 2016;96(1):72–76.
   PubMed Web of Science ®Google Scholar
• Toledo F, Silvestre JF, Mun ̃oz C. Combined therapy with low-dose omalizumab and intravenous immunoglobulin for severe atopic dermatitis. Report of four cases. J Eur Acad Dermatol Venereol. 2012;26(10):1325–1327.
   PubMed Web of Science ®Google Scholar
• Hotze M, Baurecht H, Rodríguez E, et al. Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines. Allergy. 2014;69(1):132–135.
   PubMed Web of Science ®Google Scholar
• Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol. 2005;53(2):338–340.
   PubMed Web of Science ®Google Scholar
• Iyengar SR, Hoyte EG, Loza A, et al. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol. 2013;162(1):89–93.
   PubMed Web of Science ®Google Scholar
• Lane JE, Cheyney JM, Lane TN, et al. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol. 2006;54(1):68–72.
   PubMed Web of Science ®Google Scholar
• Sanchez-Ramon S, Eguíluz-Gracia I, Rodríguez- Mazariego ME, et al. Sequential combined therapy with Omalizumab and Rituximab: a new approach to severe atopic dermatitis. J Investig Allergol Clin Immunol. 2013;23(3):190–196.
   PubMed Web of Science ®Google Scholar
• Velling P, Skowasch D, Pabst S, et al. Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: one year follow-up of omalizumab therapy. Eur J Med Res. 2011;16(9):407.
   PubMed Web of Science ®Google Scholar
• Romano C, Sellitto A, De Fanis U, et al. Omalizumab for difficult-to-treat dermatological conditions: clinical and immunological features from a retrospective real-life experience. Clin Drug Investig. 2015;35(3):159–168.
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Arm JP, Boulet LP, et al. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. J Allergy Clin Immunol. 2016;138(4):1051–1059.
   PubMed Web of Science ®Google Scholar
• Lee DE, Clark AK, Tran KA, et al. New and emerging targeted systemic therapies: a new era for atopic dermatitis. J Dermatolog Treat. 2018;29(4):364–374.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. A study evaluating the safety and efficacy of QGE031 in atopic dermatitis patients. Bethesda (MD): ClinicalTrials.gov; 2017 [cited 2017 Jun 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT01552629?term=NCT01552629&rank=1
   Google Scholar
• Simon D, Hosli S, Kostylina G, et al. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol. 2008;121(1):122–128.
   PubMed Web of Science ®Google Scholar
• Sediva A, Kayserova J, Vernerova E, et al. Anti-CD20 (rituximab) treatment for atopic eczema. J Allergy Clin Immunol. 2008;121(1):1515–1516.
   PubMed Web of Science ®Google Scholar
• McDonald BS, Jones J, Rustin M. Rituximab as a treatment for severe atopic eczema: failure to improve in three consecutive patients. Clin Exp Dermatol. 2016;41(1):45–47.
   PubMed Web of Science ®Google Scholar
• Pene J, Chevalier S, Preisser L, et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol. 2008;180(11):7423–7430.
   PubMed Web of Science ®Google Scholar
• Dhingra N, Guttman-Yassky E. A possible role for IL-17A in establishing Th2 inflammation in murine models of atopic dermatitis. J Invest Dermatol. 2014;134(8):2071–2074.
   PubMed Web of Science ®Google Scholar
• Batista DI, Perez L, Orfali RL, et al. Profile of skin barrier proteins (filaggrin, claudins 1 and 4) and Th1/Th2/Th17 cytokines in adults with atopic dermatitis. J Eur Acad Dermatol Venereol. 2015;29(6):1091–1095.
   PubMed Web of Science ®Google Scholar
• Floudas A, Saunders SP, Moran T, et al. IL-17 receptor A maintains and protects the skin barrier to prevent allergic skin inflammation. J Immunol. 2017;199(2):707–717.
   PubMed Web of Science ®Google Scholar
• Koga C, Kabashima K, Shiraishi N, et al. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol. 2008;128(11):2625–2630.
   PubMed Web of Science ®Google Scholar
• Noda S, Hashim PW, Khattri S, et al. Successful use of secukinumab in an Asian patient with severe refractory atopic dermatitis. J Invest Dermatol. 2016;136(5):S40.
   Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Secukinumab for treatment of atopic dermatitis. Bethesda (MD): ClinicalTrials.gov; 2017 [cited 2017 Jun 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT02594098?term=NCT02594098&rank=1
   Google Scholar
• Nograles KE, Zaba LC, Guttman-Yassky E, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol. 2008;159(5):1092–1102.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration [Internet]. Secukinumab. Silver Spring (MD): FDA; 2015 [cited 2017 Dec 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125504s016lbl.pdf
   Google Scholar
• Ibler K, Dam TN, Gniadecki R, et al. Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases. J Eur Acad Dermatol Venereol. 2010;24(7):837–839.
   PubMed Web of Science ®Google Scholar
• Chacko M, Weinberg JM. Efalizumab. Dermatol Ther. 2007;20(4):265–269.
   PubMed Web of Science ®Google Scholar
• Takiguchi R, Tofte S, Simpson B, et al. Efalizumab for severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol. 2007;56(2):222–227.
   PubMed Web of Science ®Google Scholar
• Lebwohl M. New developments in the treatment of psoriasis. Arch Dermatol. 2002;138(5):686–688.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349(21):2004–2013.
   PubMed Web of Science ®Google Scholar
• Baniandrés O, Pulido A, Silvente C, et al. Clinical outcomes in patients with psoriasis following discontinuation of efalizumab due to suspension of marketing authorization. Actas Dermosifiliogr. 2010;101(5):421–427.
   PubMedGoogle Scholar
• Fernández Vozmediano JM, Armario Hita JC. Nuevas perspectivas terapéuticas en dermatitis atópica (Atopic dermatitis. New therapies for the future). Med Cutan Iber Lat Am. 2011;39(1):30–36.
   Google Scholar
• Simon D, Wittwer J, Kostylina G, et al. Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema. J Allergy Clin Immunol. 2008;122(2):423.
   PubMed Web of Science ®Google Scholar
• Johnson JG, Jenkins MK. Accessory cell-derived signals required for T cell activation. Immunol Res. 1993;12(1):48–64.
   PubMed Web of Science ®Google Scholar
• Miller GT, Hochman PS, Meier W, et al. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med. 1993;178(1):211–222.
   PubMed Web of Science ®Google Scholar
• Ibler KS, Jemec GB. Novel investigational therapies for atopic dermatitis. Expert Opin Investig Drugs. 2015;24(1):61–68.
   PubMed Web of Science ®Google Scholar
• Cooper JC, Morgan G, Harding S, et al. Alefacept selectively promotes NK cell-mediated deletion of CD45RO1 human T cells. Eur J Immunol. 2003;33(3):666–675.
   PubMed Web of Science ®Google Scholar
• Moul DK, Routhouska SB, Robinson MR, et al. Alefacept for moderate to severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol. 2008;58(6):984.
   PubMed Web of Science ®Google Scholar
• Akdis CA, Akdis M, Simon HU, et al. Regulation of allergic inflammation by skin-homing T cells in allergic eczema. Int Arch Allergy Immunol. 1999;118(2–4):140–144.
   PubMed Web of Science ®Google Scholar
• Boniface K, Bernard FX, Garcia M, et al. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol. 2005;174(6):3695–3702.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Khattri S, Brunner P, et al. A pathogenic role for Th22/IL-22 in atopic dermatitis is established by a placebo-controlled trial with an anti IL- 22/ILV-094 mAb. J Invest Dermatol. 2017;137(5):S53.
   Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Randomized placebo controlled study to determine safety, pharmacodynamics and efficacy of ILV- 094 in atopic dermatitis. Bethesda (MD): ClinicalTrials.gov; 2013 [cited 2018 Aug 6] Available from: https://clinicaltrials.gov/ct2/show/NCT01941537
   Google Scholar
• Guttman-Yassky E, Brunner PM, Neumann AU, et al. Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial. J Am Acad Dermatol. 2018;78(5):872–881.e6.
   PubMed Web of Science ®Google Scholar
• Landells I, Marano C, Hsu MC, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73(4):594–603.
   PubMed Web of Science ®Google Scholar
• Fernandez-Anton Martinez MC, Alfageme Roldan F, Ciudad Blanco C, et al. Ustekinumab in the treatment of severe atopic dermatitis: a preliminary report of our experience with 4 patients. Actas Dermosifiliogr. 2014;105(3):312–313.
   PubMedGoogle Scholar
• Puya R, Alvarez-Lo ́pez M, Velez A, et al. Treatment of severe refractory adult atopic dermatitis with ustekinumab. Int J Dermatol. 2012;51(1):115–116.
   PubMed Web of Science ®Google Scholar
• Nast A, Jacobs A, Rosumeck S, et al. Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: a systematic review and meta-analysis. J Invest Dermatol. 2015;135(11):2641–2648.
   PubMed Web of Science ®Google Scholar
• Khattri S, Brunner PM, Garcet S, et al. Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis. Exp Dermatol. 2016;26(1):28–35.
   PubMed Web of Science ®Google Scholar
• Shroff A, Guttman-Yassky E. Successful use of ustekinumab therapy in refractory severe atopic dermatitis. JAAD Case Rep. 2014;1(1):25–26.
   PubMedGoogle Scholar
• Weiss D, Schaschinger M, Ristl R, et al. Ustekinumab treatment in severe atopic dermatitis: down-regulation of T-helper 2/22 expression. J Am Acad Dermatol. 2016;76(1):945–973.
   Web of Science ®Google Scholar
• Samorano LP, Hanifin JM, Simpson EL, et al. Inadequate response to ustekinumab in atopic dermatitis—a report of two patients. J Eur Acad Dermatol Venereol. 2016;30(3):522–523.
   PubMed Web of Science ®Google Scholar
• Lis-Swiety A, Skrzypek-Salamon A, Arasiewicz H, et al. Atopic dermatitis exacerbated with ustekinumab in a psoriatic patient with childhood history of atopy. Allergol Int. 2015;64(4):382–383.
   PubMed Web of Science ®Google Scholar
• Navarini AA, French LE, Hofbauer GFL. Interrupting IL-6–receptor signaling improves atopic dermatitis but associates with bacterial superinfection. J Allergy Clin Immunol. 2011;128(5):1128–1130.
   PubMed Web of Science ®Google Scholar
• Lebas D, Staumont-Sallé D, Solau-Gervais E, et al. Cutaneous manifestations during treatment with TNF-alpha blockers: 11 cases. Ann Dermatol Venereol. 2007;134(4 Pt 1):337–342.
   PubMed Web of Science ®Google Scholar
• Jacobi A, Antoni C, Manger B, et al. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol. 2005;52(3 Pt 1):522–526.
   PubMed Web of Science ®Google Scholar
• Chan JL, Davis-Reed L, Kimball AB. Counter-regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy. J Drugs Dermatol. 2004;3(3):315–318.
   PubMedGoogle Scholar
• Wright RC. Atopic dermatitis-like eruption precipitated by infliximab. J Am Acad Dermatol. 2003;49(1):160–161.
   PubMed Web of Science ®Google Scholar
• Buka RL, Resh B, Roberts B, et al. Etanercept is minimally effective in 2 children with atopic dermatitis. J Am Acad Dermatol. 2005;53(2):358–359.
   PubMed Web of Science ®Google Scholar
• Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT. 2013;2(3):e24137.
   PubMedGoogle Scholar
• Amano W, Nakajima S, Kunugi H, et al. The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling. J Allergy Clin Immunol. 2015;136(3):667–677.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase 2a randomised trial. Br J Dermatol. 2016;175(5):902–911.
   PubMed Web of Science ®Google Scholar
• Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol. 2015;73(3):395–399.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. A study to evaluate ASN002 in subjects with atopic dermatitis. Bethesda (MD): ClinicalTrials.gov; 2017 [cited 2017 Jul 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT03139981?term=NCT03139981&rank=1
   Google Scholar
• Samrao A, Berry TM, Goreshi R, et al. A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol. 2012;148(8):890–897.
   PubMedGoogle Scholar
• Jin SL, Ding SL, Lin SC. Phosphodiesterase 4 and its inhibitors in inflammatory diseases. Chang Gung Med J. 2012;35(3):197–210.
   PubMedGoogle Scholar
• Hanifin JM, Chan SC, Cheng JB, et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol. 1996;107(1):51–56.
   PubMed Web of Science ®Google Scholar
• Chan SC, Li SH, Hanifin JM. Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition. J Invest Dermatol. 1993;100(5):681–684.
   PubMed Web of Science ®Google Scholar
• Chan SC, Kim JW, Henderson WR, et al. Altered prostaglandin E2 regulation of cytokine production in atopic dermatitis. J Immunol. 1993;151(6):3345–3352.
   PubMed Web of Science ®Google Scholar
• Chan SC, Reifsnyder D, Beavo JA, et al. Immunochemical characterization of the distinct monocyte cyclic AMP phosphodiesterase from patients with atopic dermatitis. J Allergy Clin Immunol. 1993;91(6):1179–1188.
   PubMed Web of Science ®Google Scholar
• Butler JM, Chan SC, Stevens S, et al. Increased leukocyte histamine release with elevated cyclic AMP-phosphodiesterase activity in atopic dermatitis. J Allergy Clin Immunol. 1983;71(5):490–497.
   PubMed Web of Science ®Google Scholar
• Cooper KD, Kang K, Chan SC, et al. Phosphodiesterase inhibition by Ro 20-1724 reduces hyper-IgE synthesis by atopic dermatitis cells in vitro. J Invest Dermatol. 1985;84(6):477–482.
   PubMed Web of Science ®Google Scholar
• Zebda R, Paller AS. Phosphodiesterase 4 inhibitors. J Am Acad Dermatol. 2018;78(3S1):S43–S52.
   PubMed Web of Science ®Google Scholar
• Volf EM, Au SC, Dumont N, et al. A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis. J Drugs Dermatol. 2012;11(3):341–346.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Efficacy and safety study of apremilast in subjects with moderate to severe atopic dermatitis. Bethesda (MD): ClinicalTrials.gov; 2017 [cited 2018 Jun 9]. Available from: https://clinicaltrials.gov/ct2/show/NCT02087943?term=NCT02087943&rank=1
   Google Scholar
• Murata Y, Song M, Kikuchi H, et al. Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel group study of a H4 R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis. J Dermatol. 2015;42(2):129–139.
   PubMed Web of Science ®Google Scholar
• Gutzmer R, Mommert S, Gschwandtner M, et al. The histamine H4 receptor is functionally expressed on T(H)2 cells. J Allergy Clin Immunol. 2009;123(3):619–625.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. A study of JNJ-39758979 in adult Japanese patients with moderate atopic dermatitis. Bethesda (MD): ClinicalTrials.gov; 2017 [cited 2018 Jul 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT01497119?term=NCT01497119&rank=1
   Google Scholar
• Stander S, Siepmann D, Herrgott I, et al. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One. 2010;5(6):e10968.
   PubMed Web of Science ®Google Scholar
• Salomon J, Baran E. The role of selected neuropeptides in pathogenesis of atopic dermatitis. J Eur Acad Dermatol Venereol. 2008;22(2):223–228.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Proof of concept of VLY-686 in subjects with treatment-resistant pruritus associated with atopic dermatitis. Bethesda (MD): ClinicalTrials.gov; 2017 [cited 2018 Mar 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02004041?term=NCT02004041&rank=1
   Google Scholar
• ClinicalTrials.gov [Internet]. Tradipitant in treatment-resistant pruritus associated with atopic dermatitis. Bethesda (MD): ClinicalTrials.gov; 2017 [cited 2018 Apr 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT02651714?term=NCT02651714&rank=1
   Google Scholar
• ClinicalTrials.gov [Internet]. A randomized placebo-controlled study of the neurokinin-1 (NK1) receptor antagonist serlopitant prurigo nodularis (PN). Bethesda (MD): ClinicalTrials.gov; 2017 [cited 2018 Jan 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT02196324?term=NCT02196324&rank=1
   Google Scholar
• Tominaga M, Ogawa H, Takamori K. Possible roles of epidermal opioid systems in pruritus of atopic dermatitis. J Invest Dermatol. 2007;127(9):2228–2235.
   PubMed Web of Science ®Google Scholar
• Bishop KM, Visonneau S, McGuire D Development of asimadoline,a selective kappa opioid receptor agonist, for the treatment of pruritus. Paper presented at: 8th World Congress on Itch (WCI); 2015 Oct 27–29; Nara, Japan.
   Google Scholar
• Tey HL, Yosipovitch G. Targeted treatment of pruritus: a look into the future. Br J Dermatol. 2011;165(1):5–17.
   PubMed Web of Science ®Google Scholar
• Cowan A, Kehner GB, Inan S. Targeting itch with ligands selective for j opioid receptors. Handb Exp Pharmacol. 2015;226:291–314.
   PubMedGoogle Scholar
• ClinicalTrials.gov [Internet]. Safety, pharmacokinetics and preliminary efficacy of asimadoline in pruritus associated with atopic dermatitis. Bethesda (MD): ClinicalTrials.gov;2017 [cited 2018 Feb 05]. Available from: https://clinicaltrials.gov/ct2/show/NCT02475447?term=NCT02475447&rank=1
   Google Scholar
• Fajas L, Auboeuf D, Raspe E, et al. The organization, promoter analysis, and expression of the human PPAR-γ gene. J Biol Chem. 1997;272(30):18779–18789.
   PubMed Web of Science ®Google Scholar
• Kuenzli S, Saurat JH. Peroxisome proliferator-activated receptors in cutaneous biology. Br J Dermatol. 2003;149(2):229–236.
   PubMed Web of Science ®Google Scholar
• Behshad R, Cooper KD, Korman NJ. A retrospective case series review of the peroxisome proliferator-activated receptor ligand rosiglitazone in the treatment of atopic dermatitis. Arch Dermatol. 2008;144(1):84–88.
   PubMedGoogle Scholar
• Martin H. Role of PPAR-γ in inflammation. Prospects for therapeutic intervention by food components. Mutat Res. 2010;690(1–2):57–63.
   PubMed Web of Science ®Google Scholar
• Pappas A. Epidermal surface lipids. Dermatoendocrinol. 2009;1(2):72–76.
   PubMedGoogle Scholar
• Manku MS, Horrobin DF, Morse N, et al. Reduced levels of prostaglandin precursors in the blood of atopic patients: defective delta-6-desaturase function as a biochemical basis for atopy. Prostaglandins Leukot Med. 1982;9(6):615–628.
   PubMedGoogle Scholar
• Kawashima H, Tateishi N, Shiraishi A, et al. Oral administration of dihomo-gamma-linolenic acid prevents development of atopic dermatitis in NC/Nga mice. Lipids. 2008;43(1):37–43.
   PubMed Web of Science ®Google Scholar
• dsbiopharma.com [Internet]. DS biopharma announces positive top-line phase IIa trial results for DS107 as an oral treatment for moderate to severe atopic dermatitis. Dublin: (Ireland): dsbiopharma.com; 2016 [cited 2018 Jul 10]. Available from: http://www.dsbiopharma.com/2016/01/07/ds-biopharma-announces-positive-top-line-phase-iia-trial-results-for-ds107-as-an-oral-treatment-for-moderate-to-severe-atopic-dermatitis/
   Google Scholar
• ClinicalTrials.gov [Internet]. Oral DS107G in moderate to severe atopic dermatitis. Bethesda (MD): ClinicalTrials.gov; 2017. [cited 2018 Mar 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT02211417?term=NCT02211417&rank=1
   Google Scholar
• ClinicalTrials.gov [Internet]. Efficacy and safety study of orally administered DS107 in moderate to severe atopic dermatitis patients. Bethesda (MD): ClinicalTrials.gov; 2017 [cited 2018 May 16]. Available from: https://clinicaltrials.gov/ct2/show/NCT02864498?term=NCT02864498&rank=1
   Google Scholar
• Eichenfield LF, Ahluwalia J, Waldman A, et al. Current guidelines for the evaluation and management of atopic dermatitis: A comparison of the joint task force practice parameter and American Academy of Dermatology guidelines. J Allergy Clin Immunol. 2017;139(4S):S49–S57.
   PubMed Web of Science ®Google Scholar